Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Enliven Therapeutics Inc shares valued at $535,099 were sold by Lyssikatos Joseph P on Jan 20 ’26. At $26.75 per share, Lyssikatos Joseph P sold 20,000 shares. The insider’s holdings dropped to 745,188 shares worth approximately $20.14 million following the completion of this transaction.
Also, Heyman Richard A. sold 1,230 shares, netting a total of over 32,902 in proceeds. Following the sale of shares at $26.75 each, the insider now holds 23,877 shares.
Before that, Heyman Richard A. had added 1,230 shares to its account. In a trade valued at $32,853, the Director bought Enliven Therapeutics Inc shares for $26.71 each.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] plunged -0.64% to $27.03. The stock’s lowest price that day was $26.99, but it reached a high of $28.69 in the same session. During the last five days, there has been a surge of approximately 3.76%. Over the course of the year, Enliven Therapeutics Inc shares have jumped approximately 22.86%.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.32 million shares to 8.31 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 8.0 million shares. A jump of 3.8% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.74 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.74.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 39 in the next 12 months, up nearly 43.38% from the previous closing price of $27.2. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2026, with the lowest price target being 39. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2026. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
